Summary

Contact us
On November 1st, the United Kingdom (UK) published the Bletchley Declaration on the opening day of the Artificial Intelligence (AI) Safety Summit hosted at Bletchley Park, central England.This declaration, made by the UK and joined by 28 countries and international organizations, aims to promote cooperation among them regarding AI.

Why Bletchley ? It was at Bletchley Park that the Enigma code was successfully deciphered during WW2 …

International efforts are being made to examine and address the potential impact of AI systems, especially on principles such as the protection of human rights, data protection, and ethics.👉🏻 The primary focus of this declaration is on Frontier AI. These AI are defined as highly capable general-purpose AI models and specific narrow AI that could exhibit capabilities causing harm

The core concerns of the organizations revolve around the risks posed by Frontier AI, particularly in the domains of cybersecurity and biotechnology. Through international cooperation, they aim to deepen their understanding of these risks and identify actions to address them.

A regulatory approach will be considered by the participating organizations. This includes making, where appropriate, classifications and categorizations of risk based on national circumstances and applicable legal frameworks. International codes of conduct may result from this cooperation.

All AI actors are affected by this Declaration. Actors who develop Frontier AI have a significant responsibility to ensure the safety of these systems. The organizations encourage these actors to provide context-appropriate transparency and accountability in their plans to measure, monitor, and mitigate potentially harmful capabilities and associated effects, particularly to prevent misuse and issues of control, as well as the amplification of other risks.

Click here to read more

Contact us

FAQs

Our frequently questions

No items found.

Seamus Larroque

CDPO / CPIM / ISO 27005 Certified

Find out how iliomad can help your company.

[Map placeholder]
Only visible in production
38.709099
-39.182035
1.6
6d17042a3425c5b3
Your message has been received!
We'll get back to you as soon as possible.
Something went wrong, please try again.
Home

Discover our latest articles

View All Blog Posts
Diagram illustrating the EDPB three-criteria anonymisation test applied to clinical trial datasets under GDPR, with icons for record isolation, linkage and inference
July 13, 2026
DPIA
AI
Testimonial
EU Privacy Law
Regulations & Guidelines

EDPB Anonymisation Guidelines 2026 and Clinical Trial Data: What Life Sciences Organisations Must Know

EDPB Guidelines 02/2026 on anonymisation set new standards for clinical trial data. Learn the three-criteria test, enforcement lessons and compliance steps. iliomad.

Abstract digital network connecting a hospital, a regulatory building and a courtroom, representing AI governance, health data privacy and transatlantic data transfer risks in 2026
July 8, 2026
Healthtech
Regulations & Guidelines
DPIA
Regulation
LLMS

AI Triage, Biopharma Workbenches and Crumbling Data Bridges: iliomad Weekly Digest

NHS AI triage, Anthropic Claude Science, medical AI privacy risks, MHRA GxP guidance, EDPS ADM checklist and the EU-US data transfer threat explained.

A clinical data reviewer examining an automated decision output on a screen, representing human oversight in GDPR clinical trials under the EDPS ADM checklist framework
July 6, 2026
GDPR
Regulation
Clinical Trials
US Privacy Law
EU Privacy Law

Human Intervention in Automated Decision-Making: What the EDPS Checklist Means for Life Sciences

The EDPS checklist on human intervention in automated decision-making carries direct implications for GDPR clinical trials. Learn what effective oversight requires.